Increase blood pressure in patients with lipid-lowering therapy Lipitor discovery

Pfizer announced that, according to the ACC meeting in Chicago announced by the antihypertensive treatment of lipid-lowering milestone in the joint findings of the study, normal or mildly elevated blood lipids of patients with high blood lipid-lowering drug Lipitor ò (atorvastatin calcium ) Treated with placebo, lower-fatal coronary heart disease and non-fatal myocardial infarction by 36% and the lethal and non-fatal stroke by 27% to reduce cardiovascular events and revascularization of the lower 21%.
The result is more important in the ASCOT (Anglo - Scandinavian Cardiac Outcome Trial) obtained. The study started in 1998 in the United Kingdom, Ireland, Sweden, Norway, Denmark, Iceland and Finland, was the first significant effect due to the early conclusion of the lipid-lowering drug test.
ASCOT study selected a total of 19,342 patients with high blood pressure, the design is relatively new blood pressure drugs than the old step-down of the drug have more cardiovascular benefits. In addition, selected in more than half of the patients (10,305) also examined the lipid-lowering Lipitor ò compared to placebo treatment and the availability of more cardiovascular benefits. As the use of Lipitor ò patients with cardiovascular benefits are very significant, independent monitoring committee in October 2002 ahead of the end of the ASCOT lipid-lowering studies branch, which plans to study than the time of the last 2 years.
"It should be noted that these results are positive, strict control on the basis of high blood pressure," the chairman of one of the Sahlgrenska University in Gothenburg, Sweden, Professor Bjorn Dahlof said, "The results clearly show that blood pressure treatment on the basis of the increase Ò with Lipitor treatment can prevent further myocardial infarction and stroke. "
"ASCOT study to reduce cardiovascular events than we have seen in many other studies have taken place early," the chairman of one of the Royal College of Medicine, Professor Peter Sever said, "These findings are likely to how we will be treating high blood pressure, Normal or mildly elevated blood lipids in this particular patient population have an impact on the current view that these patients do not need to receive lipid-lowering therapy. "
"ASCOT study is further evidence of Lipitor ò excellent efficacy, and confirmed that Lipitor can ò broad group of patients received the benefits of lipid-lowering therapy." Pfizer Global Development Chairman Joseph Fan said Dr. Sike, " The results of blood tens of millions around the world at the same time the normal or mildly elevated blood lipids of patients provides an important up-to-date clinical information. "
Ahn Jung-Beijing Hospital of Epidemiology Research Professor Zhao Dong said: "high blood pressure and blood lipid abnormalities often co-exist in China for more than 35-year-old crowd, high blood pressure in patients with abnormal blood lipids combined as many as 37,000,000. And at the same level of blood pressure, The higher the blood lipids, heart disease and cerebrovascular disease, the higher the risk. Dyslipidemia in patients with hypertension with the cardiovascular risk is not a simple sum of the two, but 1 +1> 2. Therefore, patients with high blood pressure should be concerned about their blood lipid Situation. "
Beijing University People's Hospital, Capital University of Medical Sciences hospital colleagues Professor Hu Dayi also pointed out: "ASCOT end of the heart study how to further reduce high blood pressure in patients with myocardial infarction and stroke incidence to provide a new way of thinking. Hypertension in patients with positive step-down The treatment based on the use of lipid-lowering therapy Lipitor further significant reduction in myocardial infarction and stroke. ASCOT study of the past 2 years ahead of schedule also shows the end of the Lipitor to reduce heart attack and stroke potent. At present, China has more than 100,000,000 hypertension Patients, of which 30-50% with high cholesterol. Therefore, the majority of patients with high blood pressure should be recognized that the combined risk of high blood fat, blood lipid screening positive, if we find that abnormal blood lipids, blood pressure should be active at the same time accept the lipid-lowering therapy. "
Professor Zhao Dong ASCOT study to prove that blood pressure in patients with high blood pressure at the same time active lipid-lowering treatment, not only can reduce heart attack and stroke are also significantly lower, which the Chinese seem to have a more significant because in China due to high blood atherosclerosis Sclerosis caused by ischemic stroke of incidence on the rise. The people in the past did not recognize the lipid-lowering treatment for stroke prevention.